Advertise on podcast: Clinician's Roundtable

Host: Brian P. McDonough, MD, FAAFP Guest: Renee Williams, MD, GI New evidence from a report published in Gastroenterology demonstrates that higher adenoma detection rates (ADR) are directly associated with improved colorectal cancer detection, reinforcing ADR as a critical quality metric. Learn more about this study and its implications for optimizing screening quality and reducing missed cancers with Dr. Brian McDonough and Dr. Renee Williams, Professor of Medicine and Associate Chair for Health Equity at the NYU Grossman School of Medicine.

Guest: Christopher Cann, MD Delayed colorectal cancer screening can significantly impact not only clinical outcomes, but also patients’ long-term quality of life. Tune in to hear Dr. Christopher Cann share his insights on these lasting consequences, including the need for more extensive surgery and systemic therapies, the burden of chemotherapy-related toxicities, and the broader implications for patients like limitations on daily activities, work, and fertility. Dr. Cann is an Assistant Professor in the Department of Hematology Oncology at Fox Chase Cancer Center in Philadelphia, where he's also the Director of the Young Adult Cancer Program.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Christopher Cann, MD Timely colorectal cancer screening can mean the difference between prevention, cure, and advanced disease. Even delays as short as a year are associated with significantly increased risks of advanced cancer and mortality. Given this risk, Dr. Peter Buch speaks with Dr. Christopher Cann about the varying sensitives of available screening modalities, key patient barriers to adherence, and practical strategies to improve screening uptake. Dr. Cann is an Assistant Professor in the Department of Hematology Oncology at Fox Chase Cancer Center in Philadelphia, where he's also the Director of the Young Adult Cancer Program.

Guest: Darilyn Moyer, MD, MACP, FRCP, FIDSA, FAMWA, FEFIM How do lived experience, community dynamics, and socioeconomic realities shape infectious disease risk and patient decision making? Dr. Darilyn Moyer, Executive Vice President and Chief Executive Officer of the American College of Physicians, explains how incorporating patient context into communication and care strategies can help us better address infectious disease threats like COVID-19.

Guest: Mallik Greene, PhD A recent retrospective study evaluated how combining shared decision making and EHR-enabled workflow optimization impacted colorectal cancer (CRC) screening adherence among patients aged 45 and older. Learn more as Dr. Mallik Greene dives into the details and explains how this approach could improve patient engagement. Dr. Greene's background includes a PhD and a Postdoctoral Fellowship in Health Economics and Outcomes Research, as well as a Doctorate in Business Administration.

Presenter: Mustafa Ozcam, PhD Emerging research is redefining the role of the gut microbiome in food allergy and immune tolerance. Here to share some of the most groundbreaking findings is Dr. Mustafa Ozcam. He discusses how gut microbes metabolize allergenic proteins, shape immune development, and serve as potential biomarkers to predict oral immunotherapy success in food allergy patients. Dr. Ozcam is an Assistant Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and he spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Presenter: Marcus Shaker, MD, MSc, FAAP, FACAAI, FAAAAI Financial and space limitations are two of the most pressing issues facing allergists and immunologists in academic practice. Fortunately, negotiation principles, like BATNA and ZOPA, and disruptive innovation tactics can help address these common issues. To learn more, we recently spoke with Dr. Marcus Shaker. Not only is he a Professor of Pediatrics and Medicine at the Dartmouth Geisel School of Medicine in New Hampshire, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, & Immunology Annual Meeting.

Presenter: Sally E. Wenzel, MD, ATSF Given that severe asthma management is entering a new era of biologically driven precision, Dr. Sally Wenzel joins us to discuss the complexity within Type 2 inflammation and the limitations of relying on a single biomarker assessment. She also differentiates childhood-onset allergic asthma from adult-onset disease, underscoring how age of onset—along with underlying biology—can inform therapeutic strategy. Dr. Wenzel serves as the Director of the Asthma Institute at UPMC, and she spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Presenter: Scott Sicherer, MD Based on a randomized study, children with higher baseline thresholds of peanut reactivity achieved markedly higher rates of sustained unresponsiveness after oral immunotherapy compared with untreated peers. Learn more about this study and its clinical implications with Dr. Scott H. Sicherer. Not only is he a Professor of Pediatrics and the Director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Guest: Courtney Crawford, MD, FACS Guest: Raj Maturi, MD While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida. Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care. References: Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. …

Guest: Peter Buch, MD, FACG, AGAF, FACP From early metabolic risks to advanced liver disease, the progressive burden associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) requires timely, informed care. Hear from Dr. Peter Buch as he shares practical guidance on intervention strategies and provides a closer look at current and emerging treatments shaping patient outcomes. Dr. Buch is a board-certified clinical gastroenterologist and Associate Professor at the Frank H. Netter, MD School of Medicine at Quinnipiac University.

Host: Alexandria May, PharmD, BCPS Guest: Clay Spitler, MD Fracture patients receiving anticoagulation therapy face increased risks for bleeding and complications, particularly when urgent surgical intervention is needed. That’s why understanding how fracture type, injury severity, and anticoagulant choice influence timing and management decisions is critical to optimizing outcomes. Joining Dr. Alexandria May to discuss bleeding risk assessment, anticoagulation reversal strategies, and the importance of coordinated, protocol-driven care for fracture patients on anticoagulation is Dr. Clay Spitler. He’s an orthopedic trauma surgeon and serves as Vice Chair of Clinical Affairs for the Department of Orthopedic Surgery at the University of Alabama at Birmingham.

Guest: Peter Buch, MD, FACG, AGAF, FACP Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing liver health concern that's closely linked to obesity and other cardiometabolic risk factors, yet it remains underrecognized in clinical practice. That's why Dr. Peter Buch joins us to discuss how emerging perspectives are changing the way we think about metabolic-related liver disease. Dr. Buch is a board-certified clinical gastroenterologist and Associate Professor at the Frank H. Netter, MD School of Medicine at Quinnipiac University in Connecticut.

Guest: Sujith Cherian MD, FCCP, DAABIP Obesity introduces distinct changes to respiratory physiology that ripple across care settings—from subtle outpatient symptoms to complex ventilatory challenges in the ICU and heightened perioperative risks. Dr. Sujith Cherian explains real-world scenarios and physiologic insights to show how excess weight influences not just lung mechanics, but length of stay, postoperative recovery, and cardiopulmonary complications. Dr. Cherian is an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School. He also serves as the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston.

Guest: Sujith Cherian MD, FCCP, DAABIP With obesity rates rising to unprecedented levels, clinicians face critical challenges in managing associated complications. Hear from Dr. Sujith Cherian as he explores obesity’s systemic impact, from cardiovascular and infectious risks to medication dosing and hospital care complexities. Dr. Cherian is an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School. He also serves as the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston.